- About Us ‧ Company Introduction
- Company Introduction
- Caliway Biopharmaceuticals Co., Ltd. (Caliway) focuses on exploring novel drugs for obesity and anti-aging cosmedicine products via unique core technologyplatform to prove pharmacological efficacy and verify safety. As a pioneer in pharmaceutical industry, Caliway is committed to providing improved treatment and better life quality.
Caliway is committed to new drug development and its pharmacological research, where to involve in initial drug efficacy screening, mechanism of action, and the determination of the molecule with therapeutic effect. Following potential market trend, we screen and select molecule to conduct pharmacology, pharmacokinetics, and toxicology studies in animal. We are also capable of preforming chemistry, manufacturing and controls (CMC) studies for our candidates to bring it into drug products.
Solution to Obesity and Aging
New drugs for obesity
●Weight loss drug
●Other obesity-related diseases
Microplastic injection for anti-aging purpose - Class III combination products
●Skin whitening injections
Founding of Caliway Biopharmaceuticals Company Limited.
Establishment of GLP-compliant new drug R&D center.
Awarded the SBIR grant from the Taiwan's Ministry of Economic Affairs (MOEA) for the development project of the local liposuction injection
Localized Injection Lipolysis Agent Development Program has acquired funding from SBIR, Department of Industrial Technology, Ministry of Economic Affairs.
Increasing the capital to about US$ 2,880,000 (NT$ 86,400,000). [Authorized capital: about US$ 6,600,000 (NT$ 200,000,000)]
QC Laboratory acquired TAF ISO 17025 certificate (No. 3026).
Caliway Biomedical Laboratory has got the extending accreditation by TAF(Accreditation number: 3026)
Drug-containing Injective Hyaluronic Acid Development Program acquired funding from SBIR, Department of Industrial Technology, Ministry of Economic Affairs.
Increasing the capital to about US$ 4,850,000 (NT$ 145,500,000)
Phase II clinical trial for weight loss drug CBW-511 approved by TFDA.
CBL-514, localized injection lipolysis, named as CDE index case (IDX).
CBW-511, weight loss drug patented by TIPO.
CBL-514, localized injection lipolysis patented by TIPO.
Headquarters relocated to Xizhi Farglory U-TOWN (about 3150 m2).
CBO-012, new drugs for Osteoarthritis patented by TIPO.
Health food have acquired DOH Health Food Regulation No. A00336 by TFDA.
Conducted issuance of common stock for cash, the accrued capital increased to about US$ 6,700,000 (NT$ 201,150,000).
Began subject enrollment for phase II clinical trial of CBW-511 in National Taiwan University Hospital, China Medicine University, Mackay Memorial Hospital.
Approved as Biotech New Drug Company by Government.